ksi-301
mAbexperimental
Clinical trial activity
9 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
8
Phase 3
7
Phase 4
0
Earliest trial started Dec 26, 2018 (NCT03790852)
Timeline
Indications
Mechanism of action
- Vascular endothelial growth factor AINHIBITOR
VEGFA inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314617 ↗
- ChEMBLCHEMBL5095154 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06556368 | Phase 3 | Aug 23, 2024 | Kodiak Sciences Inc |
| NCT06270836 | Phase 3 | May 1, 2024 | Kodiak Sciences Inc |
| NCT05066230 | Phase 3 | Aug 30, 2021 | Kodiak Sciences Inc |
| NCT04964089 | Phase 3 | Jun 15, 2021 | Kodiak Sciences Inc |
| NCT04611152 | Phase 3 | Sep 30, 2020 | Kodiak Sciences Inc |
| NCT04603937 | Phase 3 | Sep 30, 2020 | Kodiak Sciences Inc |
| NCT04592419 | Phase 3 | Sep 25, 2020 | Kodiak Sciences Inc |
| NCT04049266 | Phase 2 | Aug 31, 2019 | Kodiak Sciences Inc |
| NCT03790852 | Phase 1 | Dec 26, 2018 | Kodiak Sciences Inc |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Kodiak Sciences Inc | For profit | 9 | 9 | 3 | 2018 |
1 organizations
Page 1 / 1